Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

Bibliographic Details
Main Authors:	Yang, Xinxin, Zheng, Ruiyuan, Cai, Yunpeng, Liao, Meiling, Yuan, Weien, Liu, Zhenguo
Format:	Online
Language:	English
Published:	Dove Medical Press 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356186/

Similar Items

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
by: Yang, Xinxin, et al.
Published: (2012)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
by: Kuoppamäki, Mikko, et al.
Published: (2015)

Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
by: Yang, Xinxin, et al.
Published: (2013)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
by: Tambasco, Nicola, et al.
Published: (2012)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
by: Bargiotas, Panagiotis, et al.
Published: (2013)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
by: Schaeffer, Eva, et al.
Published: (2016)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
by: Cerasa, Antonio, et al.
Published: (2015)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
by: Pahwa, Rajesh, et al.
Published: (2015)

Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson’s disease
by: Cui, Guiyun, et al.
Published: (2013)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet®), sustained‐release carbidopa‐levodopa (Sinemet® CR), and carbidopa‐levodopa‐entacapone (Stalevo®)
by: Hsu, Ann, et al.
Published: (2015)

Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®
by: Gasser, Urs E, et al.
Published: (2013)

Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats
by: Alirezaei, Masoud
Published: (2015)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
by: Guridi, J., et al.
Published: (2012)

Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease
by: Kim, Ji Hee, et al.
Published: (2015)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
by: Herz, Damian M., et al.
Published: (2016)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
by: Antonini, Angelo, et al.
Published: (2016)

Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson's Disease
by: Rajput, Ali H
Published: (2014)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
by: Herz, Damian M., et al.
Published: (2014)

Cerebellum in Levodopa-Induced Dyskinesias: The Unusual Suspect in the Motor Network
by: Kishore, Asha, et al.
Published: (2014)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
by: Teng, Long, et al.
Published: (2014)

Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
by: Cao, Xuebing, et al.
Published: (2016)

NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and â-arrestin-1 expression in parkinsonian rats
by: Wu, Na, et al.
Published: (2013)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
by: Zhang, SuFang, et al.
Published: (2014)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
by: Mao, Zhongping Lily, et al.
Published: (2016)

Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology
by: Cerasa, Antonio, et al.
Published: (2014)

Mathematical Insights into the Effects of Levodopa
by: Reed, Michael C., et al.
Published: (2012)

Thrombocytopenia Associated with Levodopa Treatment
by: Lee, Ku-Eun, et al.
Published: (2013)

Orthostatic stability with intravenous levodopa
by: Siddiqi, Shan H., et al.
Published: (2015)

The Human Experience with Intravenous Levodopa
by: Siddiqi, Shan H., et al.
Published: (2016)

Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
by: Shi, Hongjuan, et al.
Published: (2015)

Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
by: Xie, Cheng-long, et al.
Published: (2014)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
by: Mao, Zhongping, et al.
Published: (2013)

Levodopa-Responsive Benign Tremulous Parkinsonism
by: Kano, Osamu, et al.
Published: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
by: Morgan, John C., et al.
Published: (2014)

Levodopa in Mucuna pruriens and its degradation
by: Pulikkalpura, Haridas, et al.
Published: (2015)

An Adverse Drug Interaction of Haloperidol with Levodopa
by: Lucca, Jisha M, et al.
Published: (2015)

Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson’s disease
by: Wu, Na, et al.
Published: (2013)

Levodopa Reverses Cytokine-Induced Reductions in Striatal Dopamine Release
by: Felger, Jennifer C., et al.
Published: (2015)

Toward the Understanding of the Metabolism of Levodopa I. DFT Investigation of the Equilibrium Geometries, Acid-Base Properties and Levodopa-Water Complexes
by: Elroby, Shabaan A. K., et al.
Published: (2012)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
by: Lee, Phil Hyu, et al.
Published: (2011)